Gene therapy products: Structures known as plasmid DNA contain circular DNA molecules and can be genetically engineered to deliver therapeutic genes into human cells. Viruses, while viral vectors, have a natural ability to transfer genetic material into cells, and therefore some gene therapy products are derived from viruses.

Once viruses are modified to eliminate their ability to cause infectious diseases, these modified viruses can be used as vectors (vehicles) to deliver therapeutic genes into human cells. Bacterial vectors, on the other hand, can be modified to prevent them from causing infectious diseases and can then be used as vectors to deliver therapeutic genes into human tissues.

Focusing on human gene editing technology, the aims of gene editing are to disrupt harmful genes or repair mutated genes. In patient-derived cellular gene therapy products, cells are taken from the patient, genetically modified (usually using a viral vector), and then returned to the patient. In addition to these products, there are CAR-T cell therapy, CAR-NK cell therapy and CRISPR-Cas9 technologies.

It includes research and development activities aimed at the discovery and production of gene therapy products.